靶点- |
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期1960-01-01 |
|
|
|
|
|
|
最高研发阶段批准上市 |
|
首次获批日期1954-10-11 |
|
|
|
|
|
|
最高研发阶段临床3期 |
首次获批国家/地区- |
首次获批日期- |
Randomised, Double-blind, Placebo-controlled Trial Evaluating the Effects of Metronidazole Ointment in Facilitating Resolution of Non-healing Pilonidal Sinus Wounds.
Title of Study:
Randomised, double-blind, placebo-controlled trial evaluating the effects of metronidazole ointment in facilitating resolution on non-healing pilonidal sinus wounds Medical Condition Under Investigation Non-healing pilonidal sinus wounds
Study centres: 2 Centres in Turkey
Clinical Phase: Phase 2
Protocol Number: MET-PS-02
Study Design: Randomised, double-blind, placebo-controlled, parallel group study to determine the safety and efficacy of metronidazole ointment applied to the wound, following debridement in non-healing pilonidal sinus wounds.
Planned Sample Size: 80 subjects
A Randomised, Double-blind, Placebo Controlled Study of Eicosapentaenoic Acid (EPA-FFA) Gastro-resistant Capsules to Treat Hospitalised Subjects With Confirmed SARS-CoV-2
This is an double-blind, randomized, placebo controlled phase III study in hospitalized subjects with confirmed SARS-CoV-2.
/ Active, not recruiting临床3期 Randomised, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Tolerability of EPA-FFA Gastro-resistant Capsules, in Patients With Familial Adenomatous Polyposis (FAP)
2 Year randomised, double-blind, placebo-controlled, parallel group study to determine the safety and efficacy of EPA-FFA gastro resistant capsules in FAP.
100 项与 S.L.A. Pharma AG 相关的临床结果
0 项与 S.L.A. Pharma AG 相关的专利(医药)
100 项与 S.L.A. Pharma AG 相关的药物交易
100 项与 S.L.A. Pharma AG 相关的转化医学